Role of rasagiline in treating Parkinson’s disease: effect on disease progression
Irene A Malaty, Hubert H FernandezUniversity of Florida Movement Disorders Center, Gainesville, FL, USAAbstract: Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s dise...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-05-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/role-of-rasagiline-in-treating-parkinsonrsquos-disease-effect-on-disea-a3160 |